CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. by Markel, G, Lieberman, N, Katz, G, Arnon, T, Lotem, M, Drize, O, Blumberg, R, Bar-Haim, E, Mader, R, Eisenbach, L, Mandelboim, O

Long-term real-world (RW) outcomes in patients with advanced melanoma (MEL) treated with ipilimumab (IPI) and non-IPI therapies: IMAGE study by Dalle, S, Mortier, L, Corrie, P, Lotem, M, Board, R, Arance, A, Meiss, F, Terheyden, P, Gutzmer, R, Brokaw, J, Le, T, Mathias, S, Scotto, J, Lord-Bessen, J, Moshyk, A, Kotapati, S, Middleton, M

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study by Dalle, S, Mortier, L, Corrie, P, Lotem, M, Board, R, Arance, AM, Meiss, F, Terheyden, P, Gutzmer, R, Buysse, B, Oh, K, Brokaw, J, Le, TK, Mathias, SD, Scotto, J, Lord-Bessen, J, Moshyk, A, Kotapati, S, Wilkinson, J